Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 467

1.

Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.

Ringe JD, Faber H, Fahramand P, Schacht E.

J Rheumatol Suppl. 2005 Sep;76:33-40.

PMID:
16142849
2.

Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.

Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW.

Rheumatol Int. 2004 Mar;24(2):63-70. Epub 2003 Sep 25.

PMID:
14513268
3.

Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.

Reginster JY, Lecart MP, Richy F.

J Rheumatol Suppl. 2005 Sep;76:21-5.

PMID:
16142847
4.

Alfacalcidol versus plain vitamin D in inflammation induced bone loss.

Scharla SH, Schacht E, Lempert UG.

J Rheumatol Suppl. 2005 Sep;76:26-32. Review.

PMID:
16142848
5.

[Therapy of glucocorticoid-induced osteoporosis with alfacalcidol/calcium and vitamin D/calcium].

Ringe JD, Cöster A, Meng T, Schacht E, Umbach R.

Z Rheumatol. 2000 Jun;59(3):176-82. German.

PMID:
10929446
7.

Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.

Ringe JD, Cöster A, Meng T, Schacht E, Umbach R.

Calcif Tissue Int. 1999 Oct;65(4):337-40.

PMID:
10485988
8.

Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.

Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY.

Calcif Tissue Int. 2005 Mar;76(3):176-86. Epub 2005 Feb 7.

PMID:
15692726
9.

Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.

Ringe JD, Farahmand P, Schacht E.

Rheumatol Int. 2013 Mar;33(3):637-43. doi: 10.1007/s00296-012-2429-x. Epub 2012 Apr 8.

PMID:
22527138
10.

Potential of alfacalcidol for reducing increased risk of falls and fractures.

Ringe JD, Schacht E.

Rheumatol Int. 2009 Aug;29(10):1177-85. doi: 10.1007/s00296-008-0835-x. Epub 2009 Jan 22.

PMID:
19159932
11.

Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.

Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.

Epilepsia. 2013 Nov;54(11):1997-2004. doi: 10.1111/epi.12351. Epub 2013 Sep 6.

12.

Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.

Yamada S, Takagi H, Tsuchiya H, Nakajima T, Ochiai H, Ichimura A, Iwata H, Toriyama T.

Yakugaku Zasshi. 2007 Sep;127(9):1491-6.

13.

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC.

J Bone Miner Res. 2003 May;18(5):919-24.

14.

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.

Ringe JD, Farahmand P, Faber H, Dorst A.

Rheumatol Int. 2009 Jan;29(3):311-5. doi: 10.1007/s00296-008-0689-2. Epub 2008 Sep 2.

PMID:
18762944
15.

The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.

Schacht E, Richy F, Reginster JY.

J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84. Review.

16.

[Osteoporosis in rheumatoid arthritis--significance of alfacalcidol in prevention and therapy].

Schacht E.

Z Rheumatol. 2000;59 Suppl 1:10-20. Review. German.

PMID:
10769429
17.

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.

Ringe JD, Schacht E.

Rheumatol Int. 2007 Dec;28(2):103-11. Epub 2007 Aug 1. Review.

PMID:
17668216
18.

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.

Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis) research group.

Curr Med Res Opin. 2011 Jun;27(6):1273-84. doi: 10.1185/03007995.2011.580341. Epub 2011 May 10.

PMID:
21554143
19.

Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.

Schacht E, Dukas L, Richy F.

J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):174-84. Review.

20.

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.

Ringe JD, Faber H, Farahmand P, Dorst A.

Rheumatol Int. 2006 Mar;26(5):427-31. Epub 2005 Jul 7.

PMID:
16001181

Supplemental Content

Support Center